AUG 04, 2021 10:05 PM PDT

Cannabis Drug Sativex to Be Tested in Phase II Brain Tumor Trial

WRITTEN BY: Angela Dowden

A phase II trial is being planned to test the cannabis-derived drug Sativex, in patients with aggressive brain tumors.

The trial is set to take place in 15 hospitals in the UK, and will be coordinated by the Cancer Research UK Clinical Trials Unit and researchers at the University of Leeds, in northern England . 

The Brain Tumour Charity, also UK based, is fund-raising to cover the trial’s estimated costs, which are £450,00 ($627,000).

Sativex, made by GW Pharma, is a cannabis drug that comes in the form of an oral spray, containing the cannabinoids THC and CBD. The intention is to use Sativex in conjunction with chemotherapy in patients who have recurrence of a glioblastoma brain tumor following initial treatment. 

According to chief investigator Dr Susan Short, glioblastomas that are initially successfully treated nearly always regrow within a year, and there are few treatment options once this happens. However glioblastoma brain tumours have been shown to have receptors to cannabinoids on their cell surfaces, which has intrigued researchers and offered some hope that cannabis-based drugs may offer a more positive prognosis for brain tumor patients.

“Laboratory studies on glioblastoma cells have shown these drugs may slow tumour growth and work particularly well when used with temozolomide,” Dr Short explained.

A previous Phase I study of Sativex in 27 patients found that more patients were alive after one year on the drug versus placebo arm, but the trial was too small to show any significant difference in survival.

By comparison the new Phase II trial will involve ten times as many patients. It will begin early 2022, subject to the funding target being met.

Sources: University of Leeds, BBC, Pharma Times

About the Author
bsc hons
I'm a journalist and author with many year's experience of writing for both a consumer and professional audience, mostly on nutrition, health and medical prescribing. My background is food science and I'm a registered nutritionist.
You May Also Like
APR 26, 2022
Cardiology
Another Study Shows Alcohol Is Bad for the Heart
APR 26, 2022
Another Study Shows Alcohol Is Bad for the Heart
Several recent studies have shown that any amount of alcohol consumption raises cardiovascular disease risk.
APR 26, 2022
Health & Medicine
From Haze to Photosynthesis- How research may lead to better air purification methods
APR 26, 2022
From Haze to Photosynthesis- How research may lead to better air purification methods
Today, air pollution is rampant globally and is one of the most prominent issues that touches nearly every corner of the ...
MAY 04, 2022
Earth & The Environment
Pathogens can hitchhike on plastic to reach the sea
MAY 04, 2022
Pathogens can hitchhike on plastic to reach the sea
While plastic has become part of our everyday lives, its environmental impact is becoming more and more apparent, specif ...
MAY 05, 2022
Genetics & Genomics
Mapping study paves way for new treatments
MAY 05, 2022
Mapping study paves way for new treatments
A first of its kind study recently published in Nature Genetics that included 9,000 Americans of European or African anc ...
MAY 07, 2022
Neuroscience
Higher Antioxidant Levels Linked to Lower Dementia Risk
MAY 07, 2022
Higher Antioxidant Levels Linked to Lower Dementia Risk
Higher levels of antioxidants in the blood are linked to a lower risk of dementia. The corresponding study was published ...
MAY 12, 2022
Neuroscience
Links between Neuroscience and Paranormal Beliefs
MAY 12, 2022
Links between Neuroscience and Paranormal Beliefs
A recent review of 71 published parapsychology studies indicated an association between paranormal beliefs and cognitive ...
Loading Comments...